September 18, 2019
BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors
BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to clinical stage with lead Acute Myeloid Leukemia ("AML") compound BTX-A51
CHAPPAQUA, N.Y., Sept. 18, 2019 /PRNewswire/ -- BioTheryX, Inc. ("BioTheryX"), a biotechnology company creating
new classes of drugs for unmet medical needs based on multi-kinase inhibition and targeted protein degradation,
today announced the appointment of Jeffrey Edwards to its board of directors. Mr. Edwards retired from Allergan,
Inc. in February 2015 after nearly 22 years at the company. Mr. Edwards served as Executive Vice President,
Finance and Business Development, Chief Financial Officer of Allergan, Inc. from September 2005 to August 2014.
From 2003 to 2005, Mr. Edwards served as Allergan's Corporate Vice President, Corporate Development and
previously served as Senior Vice President, Treasury, Tax and Investor Relations. Mr. Edwards currently
serves on the board of directors and as Compensation Committee chairman and a member of both the Audit and
Compliance Committees of Bio-Rad Laboratories, Inc., a publicly traded medical device diagnostics company.
Mr. Edwards also serves on the board of directors and as Audit Committee chairman of FibroGen, Inc, a publicly
traded biopharmaceutical company. He is also a director of Clearside Biomedical Inc., a publicly traded
pharmaceutical company, where he is a member of both the Compensation Committee and Audit Committee. Mr.
Edwards received a Bachelor of Arts degree in Sociology from Muhlenberg College and completed the Advanced
Management Program at the Harvard Business School.
"We believe that Jeff's track record, experience and reputation in the business of biopharma are a great fit for BioTheryX as we transition from being a preclinical to a clinical stage biotechnology company with our lead compound, BTX-A51, on the cusp of human clinical trials," said David Stirling, CEO of BioTheryX. "We are delighted to have him on our Board, and we're looking forward to working with him as we also drive the lead compounds from our broad platform Protein Homeostatic Modulator ("PHM®") program toward the clinic in the burgeoning field of Targeted Protein Degradation."
In addition to Mr. Edwards, the BioTheryX Board currently includes: